Search hospitals > California > San Rafael

Kaiser Permanente-San Rafael

Claim this profile
San Rafael, California 94903
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
Conducts research for Adenocarcinoma
150 reported clinical trials
4 medical researchers
Photo of Kaiser Permanente-San Rafael in San RafaelPhoto of Kaiser Permanente-San Rafael in San RafaelPhoto of Kaiser Permanente-San Rafael in San Rafael

Summary

Kaiser Permanente-San Rafael is a medical facility located in San Rafael, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-San Rafael is involved with conducting 150 clinical trials across 306 conditions. There are 4 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Ramey D. Littell.

Area of expertise

1Cancer
Global Leader
Kaiser Permanente-San Rafael has run 41 trials for Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I
2Breast Cancer
Global Leader
Kaiser Permanente-San Rafael has run 38 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at Kaiser Permanente-San Rafael

Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Meningioma
ALK Gene Rearrangement
Skin Cancer
Cutaneous Melanoma
Brain Metastasis
Tumors
Cardiotoxicity
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Image of trial facility.

Genetic Testing

for Early-Stage Lung Cancer

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kaiser Permanente-San Rafael?
Kaiser Permanente-San Rafael is a medical facility located in San Rafael, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-San Rafael is involved with conducting 150 clinical trials across 306 conditions. There are 4 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Ramey D. Littell.